SCHEMBL16236292

SCHEMBL16236292

Nc1ncnc2c1ccn2C1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
ADK P55263 1/20 0.48
LCK P06239 1/20 0.46
HCK P08631 1/20 0.46
SRC P12931 1/20 0.46
TEK Q02763 1/20 0.46
RET P07949 1/20 0.46
DGAT1 O75907 1/20 0.44
ADORA2A P29274 3/20 0.44
PRMT5 O14744 8/20 0.43
WDR77 Q9BQA1 6/20 0.43
METTL3 Q86U44 1/20 0.43
ADORA3 P0DMS8 2/20 0.42
ADORA1 P30542 2/20 0.42
PI4KA P42356 1/20 0.42
PI4K2B Q8TCG2 1/20 0.42
PI4K2A Q9BTU6 1/20 0.42
PI4KB Q9UBF8 1/20 0.42
ADORA2B P29275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242174 0.86 ADORA2A (0.56) MEN1ADKLCKSRCRET
SCHEMBL16254729 0.82 METTL3 (0.53) MEN1ADKLCKSRCTEK
SCHEMBL16769985 0.82 PIP4K2A (0.42) MEN1LCKHCKSRCTEK
SCHEMBL30544051 0.81 PRMT5 (0.53) MEN1ADKADORA2APRMT5WDR77
SCHEMBL2740574 0.80 ADK (0.48) MEN1ADKPRMT5WDR77
SCHEMBL30782443 0.79 PIP4K2A (0.53) ADKLCKHCKSRCTEK
SCHEMBL30544119 0.78 MEN1 (0.49) MEN1ADKHCKADORA2APRMT5
SCHEMBL17830246 0.78 MEN1 (0.49) MEN1ADKADORA2APRMT5WDR77
SCHEMBL14447403 0.77 MEN1 (0.43) MEN1ADKHCKSRCADORA2A
SCHEMBL17818386 0.76 MEN1 (0.48) MEN1ADKSRCRETDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3472165-B1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2023-09-06 EP disclosed
EP-2997030-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-08-09 EP disclosed
US-9682083-B2 Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-20 US disclosed
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-06-16 US disclosed
EP-2997030-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-03-23 EP disclosed
WO-2014184069-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS RET, DCK, PRKD2 MEN1 3235/4885ADK 64/4885LCK 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.